Search
for

    Did you mean Phosphodiesterase Inhibitors?
    GlossaryPhosphodiesterase Inhibitors

    block enzymes that break down cyclic nucleotides

    Phosphodiesterase Inhibitors (PDE Inhibitors or PDEIs) are a class of drugs that block the action of phosphodiesterase enzymes, which are responsible for breaking down cyclic nucleotides like cAMP and cGMP. By inhibiting these enzymes, PDE inhibitors can increase the levels of these cyclic nucleotides, leading to various therapeutic effects such as vasodilation, anti-inflammatory actions, and improved cardiac function. These drugs are used to treat conditions like erectile dysfunction, pulmonary hypertension, and certain types of heart failure.

    Related Terms

    Learn

    5 / 801 results

      learn Caffeine

      the stimulant you know and love can be used topically to stimulate hair

      learn Pyrilutamide

      highly targeted anti-androgen that might have minimal systemic effects

      learn Cyproterone

      a synthetic anti-androgen and weak progestogen that inhibits DHT binding to androgen receptor

    Research

    5 / 560 results

    Community Join

    5 / 1000+ results

      community Could creatine trigger faster hairloss?

      in Research/Science  28 upvotes 1 year ago
      Creatine is reported by many to increase hair loss, though no scientific evidence supports this. Some use finasteride and minoxidil to manage hair loss, while others avoid creatine due to personal experiences.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 1 year ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.